TP53 and acute myeloid leukemia: These data suggested that p53 expression level could be helpful to stratify patients with AML and a diploid karyotype, currently classified as intermediate‐risk disease and that p53 expression level could help to identify patients who could possibly benefit from post-ASCT maintenance therapy.